Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Actinium Pharmaceuticals (ATNM) EBITDA Margin (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed EBITDA Margin for 3 consecutive years, with 21775.56% as the latest value for Q3 2022.

  • On a quarterly basis, EBITDA Margin fell 1899916.0% to 21775.56% in Q3 2022 year-over-year; TTM through Jun 2023 was 107368.89%, a 10378860.0% decrease, with the full-year FY2023 number at 64098.77%, down 6078770.0% from a year prior.
  • EBITDA Margin was 21775.56% for Q3 2022 at Actinium Pharmaceuticals, down from 17444.44% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 549.36% in Q1 2022 to a low of 108471.2% in Q4 2021.